A2 Biotherapeutics, Inc. | $80,000,000 | (Jan 10, 2025)
Holly | $2,200,000 | (Jan 10, 2025)
RLTYco | $20,000,000 | (Jan 10, 2025)
Certified by Founder
Lodge
Ratio Therapeutics
start up
United States
- Boston, MA
- 02/12/2021
- Unknown
- $1,500,000
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
- Industry Pharmaceutical Manufacturing
- Website https://ratiotx.com/
- LinkedIn https://www.linkedin.com/company/rat
Air | $35,000,000 | (Jan 10, 2025)
Prudentia Sciences | $7,000,000 | (Jan 10, 2025)
Biosphere | $8,800,000 | (Jan 10, 2025)
RyboDyn Inc. | $4,000,000 | (Jan 10, 2025)
RheumaGen | $15,000,000 | (Jan 10, 2025)
Light Horse Therapeutics | $62,000,000 | (Jan 10, 2025)
Abstract(US) | $4,800,000 | (Jan 10, 2025)
PrettyDamnQuick | $25,000,000 | (Jan 10, 2025)
Oxford Cancer Analytics | $11,000,000 | (Jan 10, 2025)